Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 7/20 | 1.00 |
| ▸ | HTR2C | P28335 | 4/20 | 0.68 |
| ▸ | HTR1A | P08908 | 3/20 | 0.68 |
| ▸ | HTR2B | P41595 | 3/20 | 0.68 |
| ▸ | HTR1B | P28222 | 3/20 | 0.68 |
| ▸ | HTR1D | P28221 | 2/20 | 0.68 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.68 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.68 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.68 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.68 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.68 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.63 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.62 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.62 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.62 |
| ▸ | HTR1E | P28566 | 1/20 | 0.62 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.62 |
| ▸ | HTR7 | P34969 | 1/20 | 0.62 |
| ▸ | HTR6 | P50406 | 1/20 | 0.62 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29527375 | 1.00 | HTR2A (1.00) | HTR2AHTR2CHTR1AHTR2BHTR1B | |
| SCHEMBL1305546 | 1.00 | HTR2A (1.00) | HTR2AHTR2CHTR1AHTR2BHTR1B | |
| SCHEMBL14511411 | 0.87 | HTR2A (0.77) | HTR2AHTR2CHTR1AHTR2BHTR1B | |
| SCHEMBL23649381 | 0.85 | HTR2A (0.74) | HTR2AHTR2CHTR1AHTR2BHTR1B | |
| SCHEMBL25002265 | 0.84 | HTR2A (0.73) | HTR2AHTR2CHTR1AHTR2BHTR1B | |
| SCHEMBL1304961 | 0.84 | HTR2A (0.73) | HTR2AHTR2CHTR1AHTR2BHTR1B | |
| SCHEMBL19068711 | 0.83 | HTR2A (0.72) | HTR2AHTR2CHTR1AHTR2BHTR1B | |
| SCHEMBL24913231 | 0.83 | HTR2A (0.70) | HTR2AHTR2CHTR1AHTR2BHTR1B | |
| SCHEMBL1120488 | 0.83 | HTR2A (0.70) | HTR2AHTR2CHTR1AHTR2BHTR1B | |
| SCHEMBL30811419 | 0.83 | HTR2A (0.70) | HTR2AHTR2CHTR1AHTR2BHTR1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3759075-B1 | COMPOUNDS WITH FERROPTOSIS INDUCING ACTIVITY AND METHODS OF THEIR USE | FERRO THERAPEUTICS INC (US) | 2025-07-23 | — | — | EP | disclosed |
| US-20230039846-A1 | COMPOUNDS AND METHODS OF USE | FERRO THERAPEUTICS INC (US) | 2023-02-09 | — | — | US | disclosed |
| US-20230039846-A1 | COMPOUNDS AND METHODS OF USE | FERRO THERAPEUTICS INC (US) | 2023-02-09 | — | — | US | disclosed |
| CN-112041301-A | Compounds having iron death inducing activity and methods of use thereof | 费罗治疗公司 | 2020-12-04 | — | — | CN | disclosed |
| US-20190263802-A1 | COMPOUNDS AND METHOD OF USE | MOLECULAR SKIN THERAPEUTICS, INC. | 2019-08-29 | — | — | US | disclosed |
| US-20190263802-A1 | COMPOUNDS AND METHOD OF USE | MOLECULAR SKIN THERAPEUTICS, INC. | 2019-08-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230039846-A1 | COMPOUNDS AND METHODS OF USE | AIFM2, GPX4, GPX1 | HTR2A 3134/4885HTR2C 2543/4885HTR1A 4288/4885 |
| US-20190263802-A1 | COMPOUNDS AND METHOD OF USE | AIFM2, GPX4, GPX1 | HTR2A 3059/4885HTR2C 2709/4885HTR1A 4154/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.